ADAP250117C1500
- 0.00
- 0.000.00%
Adaptimmune Therapeutics Newsroom
Adaptimmune Says CFO, Other C-Suite Officer to Step Down
Adaptimmune: Focusing Increasing Proportion of Corporate Functions in U.S. >ADAP
Express News | Adaptimmune Therapeutics PLC - Gavin Wood to Step Down as Chief Financial Officer
First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Express News | Adaptimmune Therapeutics PLC : Mizuho Cuts Target Price to $1.50 From $3
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics: Strategic Restructuring and Promising Developments Drive 'Buy' Rating
Adaptimmune Therapeutics Analyst Ratings
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim
Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) Have Lost 86%, as Stock Drops 26% This Past Week
Wells Fargo Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Adaptimmune Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results.
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
TD Cowen Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating